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Background: Posterior urethral valves (PUVs) and ureteropelvic junction obstruction
(UPJO) are congenital obstructive uropathies that may impair kidney development.
Objective: To identify genetic variants associated with kidney injury in patients
with obstructive uropathy.
Design, setting, and participants: We included 487 patients born in 1981 or later
who underwent pyeloplasty or valve resection before 18 yr of age in the discovery
phase, 102 PUV patients in a first replication phase, and 102 in a second replication
phase.
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1. Introduction
Posterior urethral valves (PUV) and ureteropelvic junction
obstruction (UPJO) are congenital anomalies of the urinary
tract that impair urinary flow. PUV affects only boys and
occurs in one in 4000 livemale births [1], while UPJO affects
one in 500 children [2]. These obstructions may perturb
kidney development and are referred to as obstructive
uropathy [3]. Obstructive uropathy is the second most
prevalent cause of end-stage kidney disease in children [4],
but long-term kidney function is variable and cannot be
predicted reliably.
Knowledge about the molecular pathways involved in
the pathophysiology of kidney injury in congenital obstruc-
tive uropathy has mainly been derived from neonatal rats
and mice with induced complete unilateral ureteral
obstruction (UUO). Kidney response to experimental UUO
involves oxidative stress, monocyte infiltration, uncon-
trolled apoptosis of tubular cells, fibroblast accumulation,
and increased deposition of extracellular matrix [3]. This is
similar to the response in human obstructed kidneys, where
the extent of monocyte infiltration correlates with the
intensity of tubulointerstitial damage, and inflammatory
molecules, such as MCP1, are upregulated [5]. In addition to
elements from proinflammatory pathways, several other
molecules have been suggested to play a pathological role in
kidney injury in obstructive uropathy in animal models
(such as angiotensin II and Tgf-b) [3,6,7]. Several of these
were confirmed in human expression studies (including
TGF-b1, REN, and EGF) [5,6,8,9]. Finally, copy number
variations (CNVs) >100 Kb were associated with kidney
failure in PUV patients [10], while polymorphisms in ACE
and AGTR2 have been associated with lower estimated
glomerular filtration rate (eGFR), chronic kidney disease,
and kidney scarring in PUV patients [11–13].
Most of the genetic studies described above focused on
candidate genes, but a hypothesis-generating approach,
such as a genome-wide association study (GWAS),may shed
new light on pathways involved in the development of
kidney injury in obstructive uropathy. In addition, genetic
variants associated with kidney function decline could be
used in prognostic modeling approaches to better predict
long-term kidney function. As no such studies have been
conducted so far, the aim of this study was to perform a
GWAS for kidney injury in obstructive uropathy. We
included patients with PUV and UPJO under the assumption
that similar genetic variants are associated with kidney
function decline in both obstructive uropathies.
2. Patients and methods
2.1. Patients
2.1.1. Discovery sample
AGORA(Aetiologic research intoGenetic andOccupational/environmental
Risk factors for Anomalies in children) is a database and biobank in the
Radboudumc (Nijmegen, The Netherlands) collecting questionnaire data,
blood/saliva samples, and phenotypic information from patients with
congenitalmalformations and their parents [14,15].We identifiedpatients
born from 1981 onwards who underwent pyeloplasty or PUV resection
before 18 yr of age in AGORA and searched the Radboudumc medical
registry for additional patients to approach for participation.
Outcome measurements and statistical analysis: Signs of kidney injury were
defined as dialysis, nephrectomy, kidney transplantation, estimated glomerular
filtration rate (eGFR) <60 ml/min/1.73 m2, high blood pressure, antihyperten-
sive medication use, proteinuria, and/or one kidney functioning at <45%. We
used x2 tests to calculate p values and odds ratios for >600 000 single-
nucleotide polymorphisms (SNPs) in the discovery sample comparing patients
with andwithout signs of kidney injurywithin 5 yr after surgery.We performed
stratified analyses for PUV and UPJO and Kaplan-Meier and Cox regression
analyses in the discovery and two replication samples for the associated SNPs,
and RNA and protein expression analyses for the associated gene in fetal tissues.
Results and limitations: Despite the small and nonhomogeneous sample, we
observed suggestive associations for six SNPs in three loci, of which rs6874819
in the CDH12 gene was the most clear (p =7.5  10–7). This SNP also seemed to
be associated with time to kidney injury in the PUV discovery and replication
samples. RNA expression analyses showed clear CDH12 expression in fetal
kidneys, which was confirmed by protein immunolocalization.
Conclusions: This study identified CDH12 as a candidate gene for kidney injury
in PUV.
Patient summary: We found that variants of the CDH12 gene increase the risk of
kidney injury in patients with extra flaps of tissue in the urethra (posterior
urethral valves). This is the first report on this gene in this context. Our study
provides interesting new information about the pathways involved and impor-
tant leads for further research for this condition.
© 2021 The Author(s). Published by Elsevier B.V. on behalf of European Association of
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2.1.2. Dutch replication sample
For replication purposes, we included patients treated in the Isala clinics,
Zwolle or UniversityMedical Center (UMC), Groningen, The Netherlands.
Owing to registration issues, we were only able to identify patients
treated in 2002 or later.
2.1.3. European replication sample
The European replication sample was derived from the 4C study [16]. In
brief, a cohort of children aged 6–17 yr with chronic kidney disease
(eGFR 10–45 ml/min/1.73 m2) was enrolled between 2010 and 2012 and
followed until 2018 at 39 pediatric nephrology centers in eight European
countries. We selected childrenwith PUV as the underlying diagnosis for
whom genotype data, longitudinal eGFR measurements, and informa-
tion on treatment changes were available.
2.2. Kidney injury
The medical files for the Dutch patients were scrutinized for
information about kidney function and for clinical descriptions.
Patients were defined as having signs of kidney injury in case of
dialysis, nephrectomy, kidney transplantation, eGFR <60 ml/min/
1.73 m2, high blood pressure, antihypertensive medication use,
proteinuria, and/or one kidney functioning at <45%. In the European
replication sample, the primary endpoint was kidney injury defined as
a composite of 50% loss of eGFR, eGFR <10 ml/min/1.73 m2, or kidney
replacement therapy (Supplementary material).
2.3. Genotyping, quality control, and imputation
The Dutch samples were genotyped by deCODE Genetics (Reykjavik,
Iceland) using Infinium OmniExpress bead chips or Global Screening
arrays (Illumina, San Diego, CA, USA). European replication
samples were genotyped using Illumina Infinium 2.5M-8 micro-
arrays. Quality control and imputation are described in the
Supplementary material.
2.4. Statistical analysis
Weexcluded patientswith<5 yr of follow-up fromour discovery sample
and compared patients with and without signs of kidney injury within
5 yr after surgery using the PLINK whole-genome data analysis toolset
(www.cog-genomics.org/plink/1.9/). Analyses were adjusted for the first
four principal components to account for population stratification. We
repeated the analyses with imputed genotypes for the area showing an
association signal and visualized the results in LocusZoom (http://
locuszoom.org/). For single-nucleotide polymorphisms (SNPs) passing
the threshold of p = 1  10–5, we examined the associations separately
for PUV and UPJO patients to verify the assumption of similar genetic
variants associated with kidney function decline in these phenotypes,
performed Kaplan-Meier and Cox regression analyses to include
130 patients with <5 yr of follow-up, and checked results in the
replication samples. In additional analyses, we adjusted the Cox
regression analysis for the most significant SNP in the PUV subgroup
of the discovery sample for the possible prognostic factors from
Table 1. In addition, we performed Cox regression analyses for the
allelic effect of this SNP in the discovery and both replication samples,
and combined the results in a meta-analysis in Review Manager 5
(https://training.cochrane.org/online-learning/core-software-
cochrane-reviews/revman/revman-5-download) using the inverse-vari-
ance method and a random-effects model.
2.5. Expression analyses
We used the Expression Atlas (www.ebi.ac.uk/gxa/home) in February
2019 to see which tissues CDH12 is expressed in [17]. We tested
expression in adult human kidney and brain and in commercially
available mRNA from human fetal kidneys (Clontech Laboratories,
Mountain View, CA, USA) via quantitative polymerase chain reaction.We
used data from our transcriptomic analysis of human organogenesis
covering 15 embryonic tissues and organs 33–55 d after conception [18]
to identify embryonic tissues in which the gene is expressed.
Table 1 – Characteristics of the patient population used in the discovery analyses
Patients, n (%)
PUV group (N = 316) UPJO group (N = 171)
Antenatal detection of urinary tract abnormalities 68 (22) 77 (45)
Birth weight <2500 g 19 (6) 14 (8)
Hospital admission within 1 wk after birth for at least 7 d 60 (19) 26 (15)
Febrile urinary tract infections in the first 4 yr of life a 108 (34) 34 (20)
Kidney abnormalities on ultrasound b 31 (10) 47 (28)
Bladder dysfunction c 130 (41) 6 (4)
Age at pyeloplasty or PUV resection
<1 yr 124 (39) 51 (30)
1–4 yr 59 (19) 49 (29)
5–12 yr 130 (41) 60 (35)
13–17 yr 3 (1) 11 (6)
Signs of kidney injury d 93 (29) 90 (53)
Dialysis, nephrectomy or kidney transplantation 17 (5) 5 (3)
eGFR <60 ml/min/1.73 m2 34 (11) 11 (6)
High blood pressure or antihypertensive medication 31 (10) 22 (13)
Proteinuria 11 (3) 6 (4)
One kidney functioning < 45% 55 (17) 74 (43)
PUV = posterior urethral valve; UPJO = ureteropelvic junction obstruction; eGFR = estimated glomerular filtration rate.
a Urinary tract infections after surgery were not taken into account.
b Kidney abnormalities defined as the presence of kidney scars or cysts, kidney dysplasia, increased echogenicity, and/or loss of parenchyma.
c Bladder dysfunction defined as training or use of medication to improve bladder function, intermittent catheterization, or vesicostoma/ureterocutaneostoma.
d Signs of kidney injury developed during the maximum follow-up period of 10 yr after surgery. Some patients developed more than one of these signs, which is
why the numbers do not add up to the total number of patients with signs of kidney injury.
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We used the Protein Atlas (www.proteinatlas.org/) in February 2019
[19] and performed immunohistochemistry of human fetal tissues as
previously described [20], using a primary antibody to CDH12 (ab71055;
Abcam, Cambridge, UK) at a dilution of 1:100. Tissue processing was as
previously described [21].
Finally, we checked the GTEx portal (https://gtexportal.org/home/) in
February 2019 to see whether the SNPs that we identified are expression




AGORA contained DNA from 433 eligible patients. We
identified 247 additional patients, of whom 151 (61%)
participated (Supplementary Fig. 1). We excluded
40 patients who did not have their first surgery (pyeloplasty
or PUV resection) in the Radboudumc, four patients with
end-stage kidney disease before surgery, and five patients
without follow-up information. Of the remaining 535 sam-
ples, 12 failed genotyping and 36 failed sample quality
control (one sample with a call rate <97%, one discordant
sex information, four related individuals, and 30 ethnic
outliers; Supplementary Fig. 2). Genotyping information for
487 patients was available for the discovery analyses
(Table 1).
3.1.2. Dutch replication sample
For replication purposes, we identified 131 patients treated
in the Isala clinics and 270 in UMC Groningen. Of these
patients, 87 (66%) and 164 (61%), respectively, participated.
We excluded three patients without follow-up information
and 26 samples that failed quality control (two samples
with a call rate <97%, one related individual, and 23 ethnic
outliers; Supplementary Fig. 2). We used genotyping
information for 222 patients in the replication analyses.
3.1.3. European replication sample
The European replication sample was derived from a study
including 704 children [16]. PUV was the underlying
diagnosis for 119 children, and all necessary information
was available for 102 of these.
3.2. Discovery analyses
We excluded 130 patients with <5 yr of follow-up and
compared 141 patients with and 216 patients without signs
of kidney injury within 5 yr after surgery. Six SNPs in three
loci reached suggestive genome-wide significance
(p < 1  10–5; Fig. 1 and Supplementary Table 1), with
rs6874819 on chromosome 5 being themost significant SNP
(p = 7.5  10–7). The other signals were from chromosomes
8 (rs2957086; p = 9.3  10–6) and 13 (rs9580025 and
rs2148707; both p = 8.2  10–6). Genotype frequencies
were in Hardy-Weinberg equilibrium in controls (p values
0.23–0.95), except for rs2957086 (p = 0.04). After imputa-
tion, rs6874819 remained the SNPwith the strongest signal.
Subgroup analyses for the six SNPs in the PUV (n = 235)
and UPJO (n = 122) groups separately showed that the
signals on chromosomes 5 and 13 were stronger in the PUV
group, while the signal on chromosome 8 was stronger in
the UPJO group (Supplementary Table 2).
Kaplan-Meier and Cox regression analyses were per-
formed to include 130 patients with <5 yr of follow-up.
These analyses included 316 PUV and 171 UPJO patients, of
whom 93 and 90, respectively, developed signs of kidney
injury within 10 yr after surgery. Variant genotypes of the
SNPs on chromosomes 5 and 13 were statistically signifi-
cantly associated with time to the development of signs of
kidney injury among PUV patients (Fig. 2A for rs6874819),
whereas the results for UPJO patients were less consistent
(Table 2).
In an additional analysis, we adjusted the Cox regression
analyses for rs6874819 among the discovery PUV patients
for the possible prognostic factors from Table 1. Although
188 patients were excluded because of missing values for
these factors, the analyses with 128 PUV patients with
47 events still gave statistically significant results very
comparable to the unadjusted results for rs6874819 (hazard
ratio for the GG genotype [HRGG] 23, p = 0.004; HRGA 2.1,
p = 0.03).
3.3. Replication analyses
Of the 222 Dutch replication samples, 78 were genotyped
on the same platform as the discovery samples, while
144 were genotyped on the Global Screening array. Only
two of the six suggestive SNPs (rs6874819 and rs2148707)
were directly genotypedwith the latter, soweused imputed
[(Fig._1)TD$FIG]
Fig. 1 – Manhattan plot of genome-wide association study results for
141 PUV and UPJO patients with signs of kidney injury 5 yr after surgery
and 216 PUV and UPJO patients without signs of kidney injury after 5 yr.
The blue line represents the threshold for suggestive genome-wide
significance (p < 1 T 10–5). The six single-nucleotide polymorphisms
above this threshold are rs6874819 (p = 7.5 T 10–7), rs9292998
(p = 3.1 T 10–6), and rs12171538 (p = 7.1 T 10–6) on chromosome 5,
rs2957086 (p = 9.3 T 10–6) on chromosome 8, and rs9580025
(p = 8.2 T 10–6) and rs2148707 (p = 8.2 T 10–6) on chromosome 13.
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Fig. 2 – Kaplan-Meier plots showing the probability of surviving without kidney injury for PUV patients by rs6874819 genotype in (A) the Dutch
discovery sample, (B) the Dutch replication sample, and (C) the European replication sample.
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genotypes for the others. We performed Kaplan-Meier and
Cox regression analyses for 102 PUV and 120 UPJO patients,
of whom 34 and 65, respectively, developed signs of kidney
injury within 10 yr after surgery. Although not statistically
significant, the associations of the SNPs on chromosome
5 were in the same direction as in the discovery sample for
PUV patients (rs6874819: HRGA 1.8, p = 0.11; HRGG 2.4,
p = 0.40; Fig. 2B). No associations were observed for the
other SNPs in the PUV group or for the UPJO group. In the
European replication sample of 102 PUV patients, the
results were very similar, with a higher risk of kidney injury
for carriers of variant genotypes on chromosome 5
(rs6874819: HRGA 1.8, p = 0.11; HRGG 3.1, p = 0.04; Table 2
and Fig. 2C).
3.4. Meta-analysis
We performed Cox regression analyses for the allelic effects
in the discovery and replication samples, and subsequently
performed a meta-analysis. This result was statistically
significant at a genome-wide level, with a HR for the G allele
of 2.3 (95% confidence interval 1.7–3.0; p = 4.1  10–9;
Table 3).
3.5. Expression analyses
Visualization of the association results using imputed
genotypes for the discovery sample in LocusZoom [22]
showed that the peak on chromosome 5 was located in an
intron of the CDH12 gene (Supplementary Fig. 3). All studies
in the Expression Atlas [17] revealed that CDH12 shows the
highest expression in human adult brain, whereas it is not
expressed in adult kidney. The NIH Epigenomics Roadmap
(http://www.roadmapepigenomics.org/) showed that
CDH12 is expressed in human fetal kidneys [23]. We
confirmed that mRNA isolated from human adult kidney
shows no CDH12 expression, whereas adult brain tissue
does. Fetal kidneys showed expression levels comparable to
those in adult brain. Transcriptomic analyses of 15 human
embryonic tissues and organs 33–55 d after conception
revealed that CDH12 is widely expressed in embryonic
tissues, with highest levels in retinal pigmented epithelium,
followed by the kidneys [18].
Immunohistochemical staining confirmed CDH12 ex-
pression in the fetal retina and kidney. At approximately
12 wk after conception, CDH12 was expressed in the
ureteric bud, the precursor of the collecting duct, and in
early condensates, where the ureteric bud induces mesen-
chymal cells to condense and start to form epithelia. In
addition, CDH12 expression was localized to proximal
tubules within the developing human kidney at 12 and
15 wk after conception (Fig. 3).
The GTEx portal showed that the associated area was an
eQTL for CDH12 in the adrenal gland. Several SNPs in the
associated area resulted in higher expression of CDH12
(Supplementary Figs. 4 and 5). Two of these SNPs were
[(Fig._3)TD$FIG]
Fig. 3 – Immunohistochemistry profile for CDH12 in the developing human kidney. (A,B) Sagittal sections through the developing kidney. Brightfield
images show CHD12 in brown, counterstained with toluidine blue. The arrow points to CHD12 within developing proximal tubules and the arrowhead
indicates the developing glomerulus. Scale bars represent 50 mm. (C–E) Immunostaining results showing clear expression of CDH12 in (C) the retina of
a 30-d-old mouse and (D,E) human kidneys 12 wk after conception (wpc). At approximately 12 wk after conception, CDH12 was expressed in the
ureteric bud, the precursor of the collecting duct, and in early condensates, where the ureteric bud induces mesenchymal cells to condense and
undergo mesenchymal-epithelial conversion, the first stage in nephron epithelial formation. Scale bars represent 100 mm. WPC stands for weeks post
conception.
E U RO P E AN URO LOGY O P EN S C I E N C E 2 8 ( 2 0 21 ) 2 6 – 3 5 31
directly genotyped in our samples. The CC genotypes
resulted in statistically significantly higher expression of
CDH12 in the adrenal gland according to the GTEx portal,
and were associated with time to the development of signs
of kidney injury in our data (Supplementary Table 3).
4. Discussion
We identified for the first time CHD12 as a gene potentially
involved in the development of kidney injury in patients
with obstructive uropathies. This result was seen among
PUV patients, but not clearly among UPJO patients, possibly
because of the different timing of PUV and UPJO develop-
ment, or because both kidneys are exposed to high urinary
pressure in PUV, whereas generally only one kidney is in
UPJO.
The association signal on chromosome 5 among PUV
patients was the most clear and the other suggested SNPs
were not associated with kidney injury in the Dutch
replication sample. Detection of the signal for CDH12
despite our small and nonhomogeneous sample suggests
that it may be an important factor. This was confirmed by
detection of the signal in the European PUV replication
sample, which was a very different patient group. Although
the primary results for rs6874819 were not statistically
significant at a genome-wide level, the result for the allelic
meta-analysis among PUV patients was. In addition, all
results show the same direction of effect. The fact that our
association signal is located in an eQTL and that CDH12 is
expressed in fetal kidneys further enhances the reliability of
our finding.
In an additional analysis, we adjusted our analyses in the
European replication sample for eGFR at study entry, which
changed the effect of rs6874819 only slightly. Since eGFR at
study entry correlates with GFR at birth, this finding
suggests that the effect of rs6874819 on kidney injury we
observed is not sufficiently explained byeffects of CHD12 on
fetal kidney development. Our hypothesis is that the
damage arises in the period when affected kidneys are
exposed to elevated pressure, which is from early fetal
development up to the postnatal period preceding surgery.
The damage may not be severe enough to display signs of
kidney injury at that point in time, but as the patients grow
and need greater filtration capacity, the affected kidneys
may fall short and the previously acquired damage begins to
show.
CDH12 is a member of the neural cadherin (N-cadherin)
gene family, which encode transmembrane calcium-de-
Table 2 – HRs for kidney injury for SNPs passing the 1T105 threshold separately for PUV and UPJO patients in the Dutch discovery and
replication samples, and for SNPs on chromosome 5 in the European replication sample
Chromosome and SNP Dutch discovery sample Dutch replication sample European replication
sample
PUV patients UPJO patients PUV patients UPJO patients PUV patients
N = 316 (93 events) N = 171 (90 events) N = 102 (34 events) N = 120 (65 events) N = 102 (54 events)
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Chromosome 5
rs6874819
AA genotype Reference Reference Reference Reference Reference
GA genotype 2.8 (1.8–4.3) 3  106 2.4 (1.5–3.8) 1  103 1.8 (0.9–3.8) 0.11 1.1 (0.5–2.2) 0.84 1.8 (0.9–3.9) 0.11
GG genotype 18 (2.4–131) 5  103 3.0 (0.7–13) 0.12 2.4 (0.3–18) 0.40 – – 3.1 (1.1–9.1) 0.04
rs9292998 a
AA genotype Reference Reference Reference Reference Reference
GA genotype 2.7 (1.7–4.1) 8  106 2.4 (1.4–4.0) 1  103 1.6 (0.7–3.5) 0.22 1.1 (0.5–2.2) 0.84 1.7 (0.8–3.8) 0.17
GG genotype 17 (2.3–127) 6  103 3.0 (0.7–12) 0.13 2.3 (0.3–17) 0.42 – – 3.1 (1.1–9.0) 0.04
rs12171538 a
TT genotype Reference Reference Reference Reference Reference
CT genotype 2.1 (1.4–3.3) 1  103 1.4 (0.9–2.3) 0.13 0.9 (0.4–1.9) 0.80 1.6 (1.0–2.8) 0.08 1.0 (0.5–1.9) 0.89
CC genotype 5.8 (2.9–12) 5  107 1.5 (0.5–4.0) 0.46 3.8 (0.9–16) 0.08 0.5 (0.1–3.6) 0.49 3.1 (1.3–7.5) 0.01
Chromosome 8
rs2957086a
AA genotype Reference Reference Reference Reference
GA genotype 1.0 (0.6–1.7) 1.0 1.2 (0.7–2.0) 0.56 1.0 (0.4–2.1) 0.91 1.2 (0.7–2.1) 0.50
GG genotype 2.3 (1.3–4.1) 3  103 2.5 (1.4–4.3) 1  103 0.7 (0.2–1.9) 0.46 0.9 (0.4–1.9) 0.78
Chromosome 18
rs9580025 a
CC genotype Reference Reference Reference Reference
TC genotype 2.0 (1.3–3.0) 2  103 1.3 (0.8–2.0) 0.30 1.1 (0.5–2.1) 0.82 0.8 (0.5–1.4) 0.45
TT genotype 2.7 (1.3–5.5) 8  103 3.8 (1.8–8.2) 1  103 – – 1.1 (0.4–3.0) 0.90
rs2148707
GG Reference Reference Reference Reference
TG 2.0 (1.3–3.0) 2  103 1.3 (0.8–2.0) 0.30 1.1 (0.5–2.1) 0.82 0.9 (0.5–1.4) 0.59
TT 2.7 (1.3–5.5) 8  103 3.8 (1.8–8.2) 1  103 – – 1.1 (0.4–3.2) 0.83
PUV = posterior urethral valve; UPJO = ureteropelvic junction obstruction; SNP = single-nucleotide polymorphism; HR = hazard ratio; CI = confidence interval.
a These SNPs were imputed in part for the Dutch replication sample.
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pendent homophilic adhesion receptors that play an
important role in cell recognition and sorting during
development [24]. CDH12 has not been described in relation
to kidney development before, but it is involved in the
progression of several cancers [24–27]. In addition, CDH12
may play a role in monocyte infiltration. Grandaliano et al
[5] showed that the extent of monocyte infiltration in
kidney tissue of children with UPJO correlated with the
degree of tubulointerstitial damage, suggesting that mono-
cyte infiltration is an important event in the development of
kidney injury in obstructive uropathy. They also showed a
striking increase in MCP1 gene expression in these kidney
tissues, which is in line with the suggestion by Diamond
et al [28] that upregulation of Mcp1, in response to an
increase in tubular pressure, stimulates monocyte influx in
a rat model of UUO. Niu et al [29] found that MCP1 action in
inducing angiogenesis is mediated via induction of a new
transcription factor that they namedMCP1-induced protein
(MCPIP). Chromatin immunoprecipitation analysis showed
that CDH12 is a target of MCPIP [29]. Ma et al [27] confirmed
that CDH12 expression is modulated by MCP1 in colorectal
cancer cells.
A drawback of our study is the relatively small sample
size. We may have missed less strong but still important
associations because our discovery analyses only had
enough power (80%) to detect variants with an allele
frequency of 30% and genotype relative risk of 2.7 or higher
under a multiplicative disease model. In addition, use of a
more homogeneous cohort of, for example, only prenatally
detected PUV, or a more homogeneous endpoint, such as
the eGFR decrease in the first yr of life, may have been
better. Instead, we used any sign of kidney injury as the
outcome to achieve larger numbers, but did not have
enough patients with specific signs to perform separate
analyses for subgroups. Nevertheless, when we performed
additional analyses that excluded one kidney functioning at
<45% from the definition of signs of kidney injury (the
diagnosis that explains why more UPJO than PUV patients
have signs of kidney injury), results for PUV patients in the
discovery sample were very comparable to the initial
results. Using a more homogeneous cohort would result in
patients beingmore comparable for other factors that could
influence the prognosis of PUV [30]. However, when we
adjusted the Cox regression analyses for PUV patients of the
discovery sample for the possible prognostic factors from
Table 1, the results were very comparable to the unadjusted
results for rs6874819. This suggests that the effect of
rs6874819 is independent from these factors and that itmay
influence the risk of signs of kidney injury in all PUV
patients, regardless of severity or management.
5. Conclusions
We hypothesize that MCP1 pathway upregulation due to an
increase in urinary tract pressure in PUV patients is
augmented in carriers of the CDH12 variant, which
facilitates monocyte infiltration and the development of
progressive kidney fibrosis and exacerbates kidney injury.
This hypothesis is in line with the importance of monocyte
infiltration in the development of kidney injury in
obstructive uropathy and provides leads for further
research. The role of CDH12 in monocyte infiltration and
the development of kidney injury in PUV, and the predictive
value of rs6874819 for the prognosis of individual PUV
patients are important future research topics, as is the
generalizability of our findings to other forms of obstructive
uropathy.
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